Wanbury Limited

WANBURY Stock View

(NSE)

64.45

211.05
Proj. ROE (%)
-
Proj. P/E (x)
-
Proj EV / EBITDA (x)
-
Proj. P/BV (x)
-
Proj. Revenue ( Cr.)
-

Stock View

-
Share on
The average score for Wanbury Limited stands at 5 against 6, three months back.

Wanbury Limited is a pharmaceutical company. The Company is engaged in the business of pharmaceutical and related activities, including research. The Company operates through two divisions: Active Pharmaceutical Ingredients (API) Business and Domestic Formulations Business. The Company through Active Pharmaceutical Ingredients (API) Business provides Metformin and Sertraline. Metformin is used for the treatment of type-1 diabetes and Sertraline is an anti-depressant. The Company through Domestic Formulations Business offers brands, which include Coriminic range, Chymonac range, Adtrol Range, Cusena, Rabiplus range, Nurture, Senasof, Nifty-SR and Zeva. The Company's subsidiaries include Wanbury Holding B.V., Wanbury Global FZE (UAE) and Ningxia Wanbury Fine Chemicals Co. Ltd. (China). It also provides Nurture-SF sugar-free protein supplements for Gestational diabetes mellitus (GDM) and Physicians (for diabetes/active lifestyle).

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
64.39
100 DMA ()
71.32
200 DMA ()
76.63
52 Weeks Range
55.05
112.00
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity